NextCure Statistics
Total Valuation
NextCure has a market cap or net worth of $7.30 million. The enterprise value is -$17.53 million.
| Market Cap | 7.30M |
| Enterprise Value | -17.53M |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NextCure has 3.61 million shares outstanding. The number of shares has increased by 53.00% in one year.
| Current Share Class | 3.61M |
| Shares Outstanding | 3.61M |
| Shares Change (YoY) | +53.00% |
| Shares Change (QoQ) | +31.60% |
| Owned by Insiders (%) | 1.27% |
| Owned by Institutions (%) | 33.61% |
| Float | 2.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.27 |
| P/TBV Ratio | 0.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.61, with a Debt / Equity ratio of 0.18.
| Current Ratio | 4.61 |
| Quick Ratio | 4.42 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -132.40% and return on invested capital (ROIC) is -75.14%.
| Return on Equity (ROE) | -132.40% |
| Return on Assets (ROA) | -66.71% |
| Return on Invested Capital (ROIC) | -75.14% |
| Return on Capital Employed (ROCE) | -180.46% |
| Weighted Average Cost of Capital (WACC) | 6.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.37M |
| Employee Count | 40 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.72% in the last 52 weeks. The beta is 1.30, so NextCure's price volatility has been higher than the market average.
| Beta (5Y) | 1.30 |
| 52-Week Price Change | -62.72% |
| 50-Day Moving Average | 7.83 |
| 200-Day Moving Average | 9.82 |
| Relative Strength Index (RSI) | 22.00 |
| Average Volume (20 Days) | 161,148 |
Short Selling Information
The latest short interest is 68,687, so 1.90% of the outstanding shares have been sold short.
| Short Interest | 68,687 |
| Short Previous Month | 58,019 |
| Short % of Shares Out | 1.90% |
| Short % of Float | 3.04% |
| Short Ratio (days to cover) | 1.70 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -56.10M |
| Pretax Income | -54.66M |
| Net Income | -54.66M |
| EBITDA | -54.29M |
| EBIT | -56.10M |
| Earnings Per Share (EPS) | -$15.32 |
Balance Sheet
The company has $29.74 million in cash and $4.91 million in debt, with a net cash position of $24.83 million or $6.87 per share.
| Cash & Cash Equivalents | 29.74M |
| Total Debt | 4.91M |
| Net Cash | 24.83M |
| Net Cash Per Share | $6.87 |
| Equity (Book Value) | 26.72M |
| Book Value Per Share | 7.41 |
| Working Capital | 24.85M |
Cash Flow
| Operating Cash Flow | -49.98M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.81M |
| Net Borrowing | n/a |
| Free Cash Flow | -49.98M |
| FCF Per Share | -$13.84 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NextCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -53.00% |
| Shareholder Yield | -53.00% |
| Earnings Yield | -749.19% |
| FCF Yield | -685.02% |
Analyst Forecast
The average price target for NextCure is $19.33, which is 856.93% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.33 |
| Price Target Difference | 856.93% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jul 14, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |